Literature DB >> 12101384

Vertebrobasilar thrombolysis with intravenous tirofiban: case report.

David S Liebeskind1, John R Pollard, Eric D Schwartz, Brett L Cucchiara, Michael L McGarvey, Robert W Hurst.   

Abstract

The use of thrombolytic agents in the setting of established cerebral infarction is limited by concerns for hemorrhagic transformation. Novel thrombolytic approaches, which have received minimal consideration, may be associated with lower risks of hemorrhage. We illustrate vertebrobasilar thrombolysis with intravenous tirofiban, a selective platelet glycoprotein IIb/IIIa receptor antagonist, and discuss the potential thrombolytic properties of this class of antithrombotics.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12101384     DOI： 10.1023/a:1016242713327

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN： 0929-5305            Impact factor:   2.300


  13 in total

1.  Rescue treatment with abciximab in acute ischemic stroke.

Authors:  K Y Lee; J H Heo; S I Lee; P H Yoon
Journal:  Neurology       Date:  2001-06-12       Impact factor: 9.910

2.  Effect of aspirin on platelet desaggregation induced by SR121566, a potent GP-IIb/IIIa antagonist.

Authors:  P Savi; A Bernat; A Lalé; C Roque; G Zamboni; J M Herbert
Journal:  Platelets       Date:  2000-02       Impact factor: 3.862

3.  Abciximab in acute ischemic stroke. A randomized, double-blind, placebo-controlled, dose-escalation study.

Authors: 
Journal:  Stroke       Date:  2000-03       Impact factor: 7.914

4.  Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis.

Authors: 
Journal:  Circulation       Date:  1997-09-02       Impact factor: 29.690

5.  A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina.

Authors: 
Journal:  N Engl J Med       Date:  1998-05-21       Impact factor: 91.245

6.  Thrombolysis of extracranial and intracranial arteries after IV abciximab.

Authors:  E Houdart; F Woimant; R Chapot; C Mounayer; C Soria; J J Merland
Journal:  Neurology       Date:  2001-06-12       Impact factor: 9.910

7.  Thrombolytic therapy of acute basilar artery occlusion. Variables affecting recanalization and outcome.

Authors:  T Brandt; R von Kummer; M Müller-Küppers; W Hacke
Journal:  Stroke       Date:  1996-05       Impact factor: 7.914

Review 8.  Synthetic inhibitors of platelet glycoprotein IIb/IIIa in clinical development.

Authors:  M Verstraete
Journal:  Circulation       Date:  2000-02-15       Impact factor: 29.690

9.  Inhibition of platelet-dependent prothrombinase activity and thrombin generation by glycoprotein IIb/IIIa receptor-directed antagonists: potential contributing mechanism of benefit in acute coronary syndromes.

Authors:  Y Li; F A Spencer; S Ball; R C Becker
Journal:  J Thromb Thrombolysis       Date:  2000-08       Impact factor: 2.300

10.  The nonpeptide glycoprotein IIb/IIIa platelet receptor antagonist SM-20302 reduces tissue plasminogen activator-induced intracerebral hemorrhage after thromboembolic stroke.

Authors:  Paul A Lapchak; Dalia M Araujo; Donghuan Song; Justin A Zivin
Journal:  Stroke       Date:  2002-01       Impact factor: 7.914
View more
  3 in total

1.  Intraarterial tirofiban thrombolysis for thromboembolisms during coil embolization for ruptured intracranial aneurysms.

Authors:  Jin Sue Jeon; Seung Hun Sheen; Gyojun Hwang; Suk Hyung Kang; Dong Hwa Heo; Yong Jun Cho
Journal:  J Cerebrovasc Endovasc Neurosurg       Date:  2012-03-31

2.  Rescue treatment with intra-arterial tirofiban infusion and emergent carotid stenting.

Authors:  Tae Jin Song; Kee Oog Lee; Dong Joon Kim; Kyung-Yul Lee
Journal:  Yonsei Med J       Date:  2008-10-31       Impact factor: 2.759

3.  Fibrinolysis and Beyond: Bridging the Gap between Local and Systemic Clot Removal.

Authors:  K Knauer; Roman Huber
Journal:  Front Neurol       Date:  2011-02-22       Impact factor: 4.003
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.